Kindeva Drug Delivery

Brought CFC-free metered-dose inhaler to market, supporting environmental sustainability.

Created inhaler technology for improved accessibility for patients with hand-breath coordination challenges.

Developed first drug-in-adhesive patch for noninvasive extended drug delivery.

Introduced a technology that initiated innovations in autoinjectors for emergency and anaphylaxis applications.

Pioneered self-administered injectors expanding emergency use adoption.

Developed the original pMDI, initiating global adoption of inhaled therapies.

Overview of comprehensive CDMO services spanning pulmonary, nasal, injectable, and transdermal platforms for end-to-end product development and supply.

Analysis of technology transfer barriers and best practices in pharmaceutical scale-up, with emphasis on regulatory and operational alignment.

Insights on using predictive engineering and digital twinning to advance drug delivery device development.

Discussion of quality management systems and proactive risk mitigation in contract manufacturing.

Strategies for efficient technology transfer, especially in complex sterile injectable programs.

Details on Annex 1 regulatory compliance and design considerations for advanced sterile fill finish manufacturing.

Summary of pulmonary and nasal device platforms, generics development, and green propellant innovation.

Information on transitioning to low-GWP inhaler propellants for regulatory and sustainability compliance.

Overview of switching to HFA152a propellants and implications for inhaler sustainability and compliance.

Explores development and challenges associated with inhaled biologic therapies.

Covers scalability, safety, and performance evaluation of microneedle patch technologies and regulatory pathways.

Describes analytical testing strategies and regulatory lifecycle support for combination drug-device products.

Technical summary on modeling spray force for pMDIs employing new propellants to guide development.

Discussion of compliance and best practices for elemental impurities testing in drug products.

Explores key issues in the development and product performance assessment for inhalers using green propellants.

Examines analytical challenges and techniques for evaluating aerosol products with high active payloads.

Shows advanced automation and control for sterile fill finish with gloveless isolator technology.

Describes purpose-built Annex 1-aligned sterile injectable infrastructure investment and development-to-commercial scale capabilities.

Details end-to-end sterile fill finish solutions, Annex 1 compliance, and process transparency from clinical to commercial supply.

Describes design and infrastructure advantages of Bridgeton facility for complex sterile injectables.

Explores growing market for GLP-1 injectables and their manufacturing and delivery system requirements.

Analysis on environmental and regulatory challenges for pMDIs, patient-centered device selection, and industry transitions to greener alternatives.

Describes the importance of strategic partnership and integrated support through every phase of the product lifecycle.

Infographic exploring the shift to sustainable pulmonary drug delivery platforms and trends in low-GWP inhalers.

Overview of end-to-end CDMO services for transdermal drug delivery platforms, including formulation, development, manufacturing, and analytical support.

Detailed examination of microneedle array patch platforms and intradermal delivery mechanisms, including customization and scalability.

Overview of medical countermeasure development and rapid supply capabilities for emergency response and responder readiness.

Advice for navigating sterile product introductions and technology transfer in the context of rapid regulatory, operational, and capacity challenges.